IN THE last decade, many reports have attested to the clinical benefits of immunotherapy in the treatment of malignant diseases. Extensive reviews of these publications have recently appeared (Nathanson, 1974; Gutterman et al., 1974) . Although experimental evidence regarding the mechanism of action of BCG and/or inactivated tumour cells on animal immune systems is abundant (Halpern et al., 1959; Old et al., 1961; Mathe et al., 1973) consistent data in humans are still scanty.
The purpose of the present study was to evaluate the effect of such a therapeutic programmne on the circulating mononuclear cell population in patients in complete remission from acute lymphocytic leukaemia (ALL). To this end, we compared a group of patients on long-term immunotherapy with a similar group receiving standard maintenance chemotherapy and with a group of normal individuals.
Thirty-one patients with ALL currently in remission were studied. Twenty of these were receiving immunotherapy and 11 chemotherapy at the time they were tested. Immunotherapy consisted of fresh live BCG (Pasteur) administered by scarification at intervals ranging from once weekly to once monthly and irradiated allogenic blast cells (108) administered Accepted 23 December 1975 intradermally (Mathe et al., 1969) . Chemotherapy consisted of weekly methotrexate and cyclophosphamide plus daily 6-mercaptopurine.
A summary of the age and sex distribution, plus the duration of maintenance treatment is presented in Table I procedures by the absolute number of mononuclear cells/mm3. Peripheral blood was collected in citrate from each subject and the mononuclear cells isolated and purified by a previously described Ficoll gradient procedure (Belpomme et al., 1974) . After at least three washings, these cells were used in the tests described below. T lymphocytes were enumerated by the E rosette test using sheep red blood cells (SRBC). Rosettes were defined as lymphocytes surrounded by at least three SRBC. We performed this test in two ways. In the first, or direct test, rosettes resulting from the incubation of mononuclear cells and SRBC alone were counted (ERFC) (Belpomme et al., 1974) . In the second, or AB serum test, AB human serum, previously decomplemented and absorbed with SRBC, was added to the incubation mixture (EABRFC). We, as others, have previously shown that this latter procedure gives a higher number of rosettes than the former (Bentwich and Kunkel, 1973; Belpomme, personal communication (Belpomme et al., 1974 The immunotherapy group demonstrated no significant difference from the normal group except in the calculated "null cells ". There was a much larger mean number of-such cells in the immunotherapy group than in the normal (P-001).
In our study the percentages and total numbers of EABRFC, mIg+ and peroxidase+ cells in normal individuals were in the range previously published (Wybran (MacLennan, 1975) . This hypothesis seems plausible since it has recently been suggested that " K " cells may be " null " cells (Greenberg et al., 1973) .
(4) They may represent T or B lymphocytes or monocytes which have lost any detectable markers, a change possibly induced by immunotherapy.
(5) A final possibility is that there may not be a true increase in these cells, but rather a redistribution between the peripheral blood and the various reticuloendothelial organs.
Further studies are in progress in our laboratory to confirm these preliminary results and to elucidate the nature of these intriguing cells.
We gratefully acknowledge the technical cooperation of Daniele Grandjon and the statistical assistance of G. Hauss. 
